Compare WLFC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | COLL |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1996 | 2015 |
| Metric | WLFC | COLL |
|---|---|---|
| Price | $120.20 | $46.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.40 |
| AVG Volume (30 Days) | 57.4K | ★ 624.2K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | 1.63 |
| Revenue | $674,381,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $16.17 | $21.41 |
| Revenue Next Year | $4.88 | $3.28 |
| P/E Ratio | ★ $7.35 | $28.72 |
| Revenue Growth | ★ 29.58 | 26.34 |
| 52 Week Low | $114.01 | $23.23 |
| 52 Week High | $229.67 | $48.18 |
| Indicator | WLFC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 73.19 |
| Support Level | $114.01 | $45.33 |
| Resistance Level | $135.00 | $46.48 |
| Average True Range (ATR) | 5.23 | 1.63 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 37.38 | 73.95 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.